Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Untargeted analysis of plasma samples from pre-eclamptic women reveals polar and apolar changes in the metabolome.

Sander KN, Kim DH, Ortori CA, Warren AY, Anyanwagu UC, Hay DP, Broughton Pipkin F, Khan RN, Barrett DA.

Metabolomics. 2019 Nov 27;15(12):157. doi: 10.1007/s11306-019-1600-8.

PMID:
31773355
2.

Fumarate metabolic signature for the detection of Reed Syndrome in humans.

Casey RT, McLean MA, Challis BG, McVeigh TP, Warren AY, Mendil L, Houghton R, De Sanctis S, Kosmoliaptsis V, Sandford RN, Gallagher FA, Maher ER.

Clin Cancer Res. 2019 Oct 21. pii: clincanres.1729.2019. doi: 10.1158/1078-0432.CCR-19-1729. [Epub ahead of print]

PMID:
31636096
3.

Spatiotemporal immune zonation of the human kidney.

Stewart BJ, Ferdinand JR, Young MD, Mitchell TJ, Loudon KW, Riding AM, Richoz N, Frazer GL, Staniforth JUL, Vieira Braga FA, Botting RA, Popescu DM, Vento-Tormo R, Stephenson E, Cagan A, Farndon SJ, Polanski K, Efremova M, Green K, Del Castillo Velasco-Herrera M, Guzzo C, Collord G, Mamanova L, Aho T, Armitage JN, Riddick ACP, Mushtaq I, Farrell S, Rampling D, Nicholson J, Filby A, Burge J, Lisgo S, Lindsay S, Bajenoff M, Warren AY, Stewart GD, Sebire N, Coleman N, Haniffa M, Teichmann SA, Behjati S, Clatworthy MR.

Science. 2019 Sep 27;365(6460):1461-1466. doi: 10.1126/science.aat5031.

PMID:
31604275
4.

Pharmacological profile of vascular activity of human stem villous arteries.

Sander KN, Ali TY, Warren AY, Hay DP, Broughton Pipkin F, Barrett DA, Khan RN.

Placenta. 2019 Dec;88:12-19. doi: 10.1016/j.placenta.2019.09.009. Epub 2019 Sep 17.

PMID:
31574379
5.

Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways.

Barrett T, Slough R, Sushentsev N, Shaida N, Koo BC, Caglic I, Kozlov V, Warren AY, Thankappannair V, Pinnock C, Shah N, Saeb-Parsy K, Gnanapragasam VJ, Sala E, Kastner C.

Clin Radiol. 2019 Nov;74(11):894.e1-894.e9. doi: 10.1016/j.crad.2019.06.004. Epub 2019 Jul 6.

PMID:
31288924
6.

Molecular imaging of the prostate: Comparing total sodium concentration quantification in prostate cancer and normal tissue using dedicated 13 C and 23 Na endorectal coils.

Barrett T, Riemer F, McLean MA, Kaggie JD, Robb F, Warren AY, Graves MJ, Gallagher FA.

J Magn Reson Imaging. 2019 May 13. doi: 10.1002/jmri.26788. [Epub ahead of print]

PMID:
31081564
7.

Defining the incremental value of 3D T2-weighted imaging in the assessment of prostate cancer extracapsular extension.

Caglic I, Povalej Brzan P, Warren AY, Bratt O, Shah N, Barrett T.

Eur Radiol. 2019 Oct;29(10):5488-5497. doi: 10.1007/s00330-019-06070-6. Epub 2019 Mar 18.

8.

A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma.

Syafruddin SE, Rodrigues P, Vojtasova E, Patel SA, Zaini MN, Burge J, Warren AY, Stewart GD, Eisen T, Bihary D, Samarajiwa SA, Vanharanta S.

Nat Commun. 2019 Mar 11;10(1):1152. doi: 10.1038/s41467-019-09116-x.

9.

Rare Abdominal Cutaneous Presentation of Clear Cell Renal Cell Carcinoma: A Case Report.

Osen ER, Warren AY.

Urology. 2019 May;127:e8-e9. doi: 10.1016/j.urology.2019.01.028. Epub 2019 Feb 8.

PMID:
30738883
10.

Repeatability of diffusion-weighted MRI of the prostate using whole lesion ADC values, skew and histogram analysis.

Barrett T, Lawrence EM, Priest AN, Warren AY, Gnanapragasam VJ, Gallagher FA, Sala E.

Eur J Radiol. 2019 Jan;110:22-29. doi: 10.1016/j.ejrad.2018.11.014. Epub 2018 Nov 17.

11.

Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation.

Gaur S, Lay N, Harmon SA, Doddakashi S, Mehralivand S, Argun B, Barrett T, Bednarova S, Girometti R, Karaarslan E, Kural AR, Oto A, Purysko AS, Antic T, Magi-Galluzzi C, Saglican Y, Sioletic S, Warren AY, Bittencourt L, Fütterer JJ, Gupta RT, Kabakus I, Law YM, Margolis DJ, Shebel H, Westphalen AC, Wood BJ, Pinto PA, Shih JH, Choyke PL, Summers RM, Turkbey B.

Oncotarget. 2018 Sep 18;9(73):33804-33817. doi: 10.18632/oncotarget.26100. eCollection 2018 Sep 18.

12.

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.

Warren AY, Massie CE, Watt K, Luko K, Orafidiya F, Selth LA, Mohammed H, Chohan BS, Menon S, Baridi A, Zhao W, Escriu C, Pungsrinont T, D'Santos C, Yang X, Taylor C, Qureshi A, Zecchini VR, Shaw GL, Dehm SM, Mills IG, Carroll JS, Tilley WD, McEwan IJ, Baniahmad A, Neal DE, Asim M.

Oncogene. 2019 Feb;38(7):1136-1150. doi: 10.1038/s41388-018-0501-z. Epub 2018 Sep 20.

13.

WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies.

Warren AY, Harrison D.

World J Urol. 2018 Dec;36(12):1913-1926. doi: 10.1007/s00345-018-2447-8. Epub 2018 Aug 19. Review.

14.

Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors.

Young MD, Mitchell TJ, Vieira Braga FA, Tran MGB, Stewart BJ, Ferdinand JR, Collord G, Botting RA, Popescu DM, Loudon KW, Vento-Tormo R, Stephenson E, Cagan A, Farndon SJ, Del Castillo Velasco-Herrera M, Guzzo C, Richoz N, Mamanova L, Aho T, Armitage JN, Riddick ACP, Mushtaq I, Farrell S, Rampling D, Nicholson J, Filby A, Burge J, Lisgo S, Maxwell PH, Lindsay S, Warren AY, Stewart GD, Sebire N, Coleman N, Haniffa M, Teichmann SA, Clatworthy M, Behjati S.

Science. 2018 Aug 10;361(6402):594-599. doi: 10.1126/science.aat1699.

15.

NF-κB-Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma Metastasis.

Rodrigues P, Patel SA, Harewood L, Olan I, Vojtasova E, Syafruddin SE, Zaini MN, Richardson EK, Burge J, Warren AY, Stewart GD, Saeb-Parsy K, Samarajiwa SA, Vanharanta S.

Cancer Discov. 2018 Jul;8(7):850-865. doi: 10.1158/2159-8290.CD-17-1211. Epub 2018 Jun 6.

16.

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Lu YJ, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, Nicol D, Tavaré S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, Corbishley C; CAMCAP Study Group, de Bono J, Attard G, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C; TCGA Consortium, Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal DE, Cooper CS, Eeles RA.

Nat Genet. 2018 May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. Epub 2018 Apr 16.

17.

A comparison of operative and margin outcomes from surgeon learning curves in robot assisted radical prostatectomy in a changing referral practice.

Jaulim A, Srinivasan A, Hori S, Kumar N, Warren AY, Shah NC, Gnanapragasam VJ.

Ann R Coll Surg Engl. 2018 Mar;100(3):226-229. doi: 10.1308/rcsann.2018.0001. Epub 2018 Feb 27.

18.

Diagnostic evaluation of magnetization transfer and diffusion kurtosis imaging for prostate cancer detection in a re-biopsy population.

Barrett T, McLean M, Priest AN, Lawrence EM, Patterson AJ, Koo BC, Patterson I, Warren AY, Doble A, Gnanapragasam VJ, Kastner C, Gallagher FA.

Eur Radiol. 2018 Aug;28(8):3141-3150. doi: 10.1007/s00330-017-5169-1. Epub 2017 Dec 8.

19.

Sub-differentiating equivocal PI-RADS-3 lesions in multiparametric magnetic resonance imaging of the prostate to improve cancer detection.

Hansen NL, Koo BC, Warren AY, Kastner C, Barrett T.

Eur J Radiol. 2017 Oct;95:307-313. doi: 10.1016/j.ejrad.2017.08.017. Epub 2017 Aug 24.

PMID:
28987685
20.

Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review.

Casey RT, Warren AY, Martin JE, Challis BG, Rattenberry E, Whitworth J, Andrews KA, Roberts T, Clark GR, West H, Smith PS, Docquier FM, Rodger F, Murray V, Simpson HL, Wallis Y, Giger O, Tran M, Tomkins S, Stewart GD, Park SM, Woodward ER, Maher ER.

J Clin Endocrinol Metab. 2017 Nov 1;102(11):4013-4022. doi: 10.1210/jc.2017-00562. Review.

21.

Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.

Camacho N, Van Loo P, Edwards S, Kay JD, Matthews L, Haase K, Clark J, Dennis N, Thomas S, Kremeyer B, Zamora J, Butler AP, Gundem G, Merson S, Luxton H, Hawkins S, Ghori M, Marsden L, Lambert A, Karaszi K, Pelvender G, Massie CE, Kote-Jarai Z, Raine K, Jones D, Howat WJ, Hazell S, Livni N, Fisher C, Ogden C, Kumar P, Thompson A, Nicol D, Mayer E, Dudderidge T, Yu Y, Zhang H, Shah NC, Gnanapragasam VJ; CRUK-ICGC Prostate Group, Isaacs W, Visakorpi T, Hamdy F, Berney D, Verrill C, Warren AY, Wedge DC, Lynch AG, Foster CS, Lu YJ, Bova GS, Whitaker HC, McDermott U, Neal DE, Eeles R, Cooper CS, Brewer DS.

PLoS Genet. 2017 Sep 25;13(9):e1007001. doi: 10.1371/journal.pgen.1007001. eCollection 2017 Sep.

22.

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.

Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, McDuffus LA, Mascalchi P, Shaw G, Dev H, Wadhwa K, Wijnhoven P, Forment JV, Lyons SR, Lynch AG, O'Neill C, Zecchini VR, Rennie PS, Baniahmad A, Tavaré S, Mills IG, Galanty Y, Crosetto N, Schultz N, Neal D, Helleday T.

Nat Commun. 2017 Aug 29;8(1):374. doi: 10.1038/s41467-017-00393-y.

23.

DESNT: A Poor Prognosis Category of Human Prostate Cancer.

Luca BA, Brewer DS, Edwards DR, Edwards S, Whitaker HC, Merson S, Dennis N, Cooper RA, Hazell S, Warren AY; CancerMap Group, Eeles R, Lynch AG, Ross-Adams H, Lamb AD, Neal DE, Sethia K, Mills RD, Ball RY, Curley H, Clark J, Moulton V, Cooper CS.

Eur Urol Focus. 2018 Dec;4(6):842-850. doi: 10.1016/j.euf.2017.01.016. Epub 2017 Mar 6.

24.

Adjuvant chemotherapy and follow-up for recurrences in localized testicular cancer.

Boulos S, Mazhar D, Warren AY, Wong HH.

Future Oncol. 2017 May;13(11):947-950. doi: 10.2217/fon-2017-0047. No abstract available.

25.

Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.

Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, McDade SS, Eden CG, Foster C, Mills IG, Neal DE, Mason MD, Kay EW, Waugh DJ, Harkin DP, Watson RW, Clarke NW, Kennedy RD.

Eur Urol. 2017 Oct;72(4):509-518. doi: 10.1016/j.eururo.2017.03.027. Epub 2017 Apr 10.

26.

Corrigendum to "Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study" [EBioMedicine 2 (9) (2015) 1133-1144].

Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Grönberg H, Neal DE; CamCaP Study Group.

EBioMedicine. 2017 Mar;17:238. doi: 10.1016/j.ebiom.2017.03.010. Epub 2017 Mar 8. No abstract available.

27.

Corrigendum to "Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity" [Mol. Cell Endocrinol. 440 (2016) 138-150].

Nelson AW, Groen AJ, Miller JL, Warren AY, Holmes KA, Tarulli GA, Tilley WD, Katzenellenbogen BS, Hawse JR, Gnanapragasam VJ, Carroll JS.

Mol Cell Endocrinol. 2017 Mar 5;443:175. doi: 10.1016/j.mce.2017.01.048. No abstract available.

28.

Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer.

Hori S, Wadhwa K, Pisupati V, Zecchini V, Ramos-Montoya A, Warren AY, Neal DE, Gnanapragasam VJ.

Int J Cancer. 2017 Apr 15;140(8):1881-1887. doi: 10.1002/ijc.30604. Epub 2017 Jan 30.

29.

Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity.

Nelson AW, Groen AJ, Miller JL, Warren AY, Holmes KA, Tarulli GA, Tilley WD, Katzenellenbogen BS, Hawse JR, Gnanapragasam VJ, Carroll JS.

Mol Cell Endocrinol. 2017 Jan 15;440:138-150. doi: 10.1016/j.mce.2016.11.016. Epub 2016 Nov 23. Erratum in: Mol Cell Endocrinol. 2017 Mar 5;443:175.

30.

Improving clinical prognostic stratification models for men with prostate cancer: a practical step closer to more individualized care without added costs.

Gnanapragasam VJ, Warren AY.

BJU Int. 2017 Mar;119(3):366-367. doi: 10.1111/bju.13721. Epub 2016 Dec 10. Review. No abstract available.

31.

Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.

Hansen NL, Kesch C, Barrett T, Koo B, Radtke JP, Bonekamp D, Schlemmer HP, Warren AY, Wieczorek K, Hohenfellner M, Kastner C, Hadaschik B.

BJU Int. 2017 Nov;120(5):631-638. doi: 10.1111/bju.13711. Epub 2016 Dec 21.

32.

Comparison of initial and tertiary centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy.

Hansen NL, Koo BC, Gallagher FA, Warren AY, Doble A, Gnanapragasam V, Bratt O, Kastner C, Barrett T.

Eur Radiol. 2017 Jun;27(6):2259-2266. doi: 10.1007/s00330-016-4635-5. Epub 2016 Oct 24.

33.

Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre.

Gnanapragasam VJ, Thurtle D, Srinivasan A, Volanis D, George A, Lophatananon A, Stearn S, Warren AY, Lamb AD, Shaw G, Sharma N, Thomas BC, Tran MG, Neal DE, Shah NC.

BJU Int. 2016 Nov;118(5):779-784. doi: 10.1111/bju.13513. Epub 2016 May 24.

34.

HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.

Ross-Adams H, Ball S, Lawrenson K, Halim S, Russell R, Wells C, Strand SH, Ørntoft TF, Larson M, Armasu S, Massie CE, Asim M, Mortensen MM, Borre M, Woodfine K, Warren AY, Lamb AD, Kay J, Whitaker H, Ramos-Montoya A, Murrell A, Sørensen KD, Fridley BL, Goode EL, Gayther SA, Masters J, Neal DE, Mills IG.

Oncotarget. 2016 Nov 15;7(46):74734-74746. doi: 10.18632/oncotarget.12543.

35.

Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panel.

Thomas BC, Kay JD, Menon S, Vowler SL, Dawson SN, Bucklow LJ, Luxton HJ, Johnston T, Massie CE, Pugh M, Warren AY, Barker P, Burling K, Lynch AG, George A, Burge J, Corcoran M, Stearn S, Lamb AD, Sharma NL, Shaw GL, Neal DE, Whitaker HC.

Endocr Relat Cancer. 2016 Oct;23(10):797-812. doi: 10.1530/ERC-16-0287. Epub 2016 Aug 30.

PMID:
27578825
36.

Evaluating Prostate Cancer Using Fractional Tissue Composition of Radical Prostatectomy Specimens and Pre-Operative Diffusional Kurtosis Magnetic Resonance Imaging.

Lawrence EM, Warren AY, Priest AN, Barrett T, Goldman DA, Gill AB, Gnanapragasam VJ, Sala E, Gallagher FA.

PLoS One. 2016 Jul 28;11(7):e0159652. doi: 10.1371/journal.pone.0159652. eCollection 2016.

37.

Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy.

Madhu B, Shaw GL, Warren AY, Neal DE, Griffiths JR.

Metabolomics. 2016;12:120. Epub 2016 Jun 30.

38.

Tubular epithelial cells in renal clear cell carcinoma express high RIPK1/3 and show increased susceptibility to TNF receptor 1-induced necroptosis.

Al-Lamki RS, Lu W, Manalo P, Wang J, Warren AY, Tolkovsky AM, Pober JS, Bradley JR.

Cell Death Dis. 2016 Jun 30;7(6):e2287. doi: 10.1038/cddis.2016.184.

39.

Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma.

Al-Lamki RS, Wang J, Yang J, Burrows N, Maxwell PH, Eisen T, Warren AY, Vanharanta S, Pacey S, Vandenabeele P, Pober JS, Bradley JR.

Oncotarget. 2016 Apr 26;7(17):24111-24. doi: 10.18632/oncotarget.8125.

40.

Gene regulatory mechanisms underpinning prostate cancer susceptibility.

Whitington T, Gao P, Song W, Ross-Adams H, Lamb AD, Yang Y, Svezia I, Klevebring D, Mills IG, Karlsson R, Halim S, Dunning MJ, Egevad L, Warren AY, Neal DE, Grönberg H, Lindberg J, Wei GH, Wiklund F.

Nat Genet. 2016 Apr;48(4):387-97. doi: 10.1038/ng.3523. Epub 2016 Mar 7.

PMID:
26950096
41.

Investigating the ability of multiparametric MRI to exclude significant prostate cancer prior to transperineal biopsy.

Serrao EM, Barrett T, Wadhwa K, Parashar D, Frey J, Koo BC, Warren AY, Doble A, Kastner C, Gallagher FA.

Can Urol Assoc J. 2015 Nov-Dec;9(11-12):E853-8. doi: 10.5489/cuaj.2895. Epub 2015 Dec 14.

42.

Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.

Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Esmaeili M, Selth LA, Zecchini HI, Luko K, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, Vowler SL, Zecchini VR, Shaw G, Hessenkemper W, Russell R, Mohammed H, Stefanos N, Lynch AG, Grigorenko E, D'Santos C, Taylor C, Lamb A, Sriranjan R, Yang J, Stark R, Dehm SM, Rennie PS, Carroll JS, Griffiths JR, Tavaré S, Mills IG, McEwan IJ, Baniahmad A, Tilley WD, Neal DE.

J Natl Cancer Inst. 2015 Dec 11;108(5). doi: 10.1093/jnci/djv371. Print 2016 May.

43.

Ratio of Tumor to Normal Prostate Tissue Apparent Diffusion Coefficient as a Method for Quantifying DWI of the Prostate.

Barrett T, Priest AN, Lawrence EM, Goldman DA, Warren AY, Gnanapragasam VJ, Sala E, Gallagher FA.

AJR Am J Roentgenol. 2015 Dec;205(6):W585-93. doi: 10.2214/AJR.15.14338.

PMID:
26587948
44.

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.

Shaw GL, Whitaker H, Corcoran M, Dunning MJ, Luxton H, Kay J, Massie CE, Miller JL, Lamb AD, Ross-Adams H, Russell R, Nelson AW, Eldridge MD, Lynch AG, Ramos-Montoya A, Mills IG, Taylor AE, Arlt W, Shah N, Warren AY, Neal DE.

Eur Urol. 2016 Aug;70(2):214-8. doi: 10.1016/j.eururo.2015.10.042. Epub 2015 Nov 10.

45.

Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.

Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Grönberg H, Neal DE; CamCaP Study Group.

EBioMedicine. 2015 Jul 29;2(9):1133-44. doi: 10.1016/j.ebiom.2015.07.017. eCollection 2015 Sep. Erratum in: EBioMedicine. 2017 Mar;17 :238.

46.

Prostatic relapse of an undifferentiated teratoma 24 years after orchidectomy.

Janowitz T, Welsh S, Warren AY, Robson J, Thomas B, Shaw A, Ainsworth NL, Neal DE, Mazhar D.

BMC Res Notes. 2015 Oct 1;8:524. doi: 10.1186/s13104-015-1445-9.

47.

Targeted transperineal biopsy of the prostate has limited additional benefit over background cores for larger MRI-identified tumors.

Barrett T, Patterson AJ, Koo BC, Wadhwa K, Warren AY, Doble A, Gnanapragasam VJ, Kastner C, Gallagher FA.

World J Urol. 2016 Apr;34(4):501-8. doi: 10.1007/s00345-015-1650-0. Epub 2015 Aug 4.

48.

Caspase-1-mediated cytokine release from gestational tissues, placental, and cord blood.

Maneta E, Warren AY, Hay DP, Khan RN.

Front Physiol. 2015 Jun 23;6:186. doi: 10.3389/fphys.2015.00186. eCollection 2015.

49.

Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer.

Pertega-Gomes N, Vizcaino JR, Felisbino S, Warren AY, Shaw G, Kay J, Whitaker H, Lynch AG, Fryer L, Neal DE, Massie CE.

Oncotarget. 2015 Aug 28;6(25):21675-84.

50.

Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.

Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, Dennis N, Merson S, Leongamornlert D, Zamora J, Corbishley C, Thomas S, Nik-Zainal S, Ramakrishna M, O'Meara S, Matthews L, Clark J, Hurst R, Mithen R, Bristow RG, Boutros PC, Fraser M, Cooke S, Raine K, Jones D, Menzies A, Stebbings L, Hinton J, Teague J, McLaren S, Mudie L, Hardy C, Anderson E, Joseph O, Goody V, Robinson B, Maddison M, Gamble S, Greenman C, Berney D, Hazell S, Livni N; ICGC Prostate Group, Fisher C, Ogden C, Kumar P, Thompson A, Woodhouse C, Nicol D, Mayer E, Dudderidge T, Shah NC, Gnanapragasam V, Voet T, Campbell P, Futreal A, Easton D, Warren AY, Foster CS, Stratton MR, Whitaker HC, McDermott U, Brewer DS, Neal DE.

Nat Genet. 2015 Jun;47(6):689. doi: 10.1038/ng0615-689b. No abstract available.

Supplemental Content

Loading ...
Support Center